Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
Euroapi (ENXTPA:EAPI) Stock Sees Fair Value Cut As JPMorgan Rebased Expectations Euroapi is back in focus after analysts cut the official price target from €2.90 to €1.70, with fair value in the reference model shifting from €1.48 to €1.20. Recent commentary, including the latest move from JPMorgan to a €1.70 target, shows how the market is resetting its view of Euroapi to match updated expectations. Read on to see what this may indicate for you and how to track the next steps in the Euroapi story. Analyst Price Targets don't always capture the full story. Head over to... | ||
LL'Usine Nouvelle | ||
FFrance 3 Régions | ||
How The Euroapi (ENXTPA:EAPI) Investment Narrative Is Resetting Around Lower Analyst Targets Euroapi’s indicative fair value has been reset from €3.08 to €2.00, with current analyst targets clustering in a tighter range around €1 to €2. For you as an investor, that shift reflects a mix of more cautious and more conservative views, with bullish commentators pointing to lowered expectations and bearish voices highlighting weaker assumptions as key reasons for the new range. Read on to see how to track these changing signals and what to watch as the Euroapi story continues to... | ||